OOIR: Observatory of International Research

Papers

(The median citation count of JACC-Heart Failure is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Complete Hemodynamic Profiling With Pulmonary Artery Catheters in Cardiogenic Shock Is Associated With Lower In-Hospital Mortality	197
A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock	171
A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction	158
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF	137
Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post–Coronavirus Disease	137
Heart Failure Drug Treatment—Inertia, Titration, and Discontinuation	97
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction	94
N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes	92
Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19	88
Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy	78
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists	77
Advanced Heart Failure Epidemiology and Outcomes	71
COVID-19 in Heart Transplant Recipients	68
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy	66
Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes	59
Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in Diabetes	59
Hemocompatibility-Related Adverse Events and Survival on Venoarterial Extracorporeal Life Support	57
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure	56
A Pragmatic Approach to Weaning Temporary Mechanical Circulatory Support	54
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF	54
Renal Compression in Heart Failure	52
Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction	48
Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients	47
Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF	46
Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines	45

Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure	45
Timing of Active Left Ventricular Unloading in Patients on Venoarterial Extracorporeal Membrane Oxygenation Therapy	43
The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials	41
Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction	40
Acute Myocarditis Associated With Desmosomal Gene Variants	39
Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis	36
Prediction of Survival After Implantation of a Fully Magnetically Levitated Left Ventricular Assist Device	36
ECMO as a Bridge to Left Ventricular Assist Device or Heart Transplantation	35
Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction	35
Drug Layering in Heart Failure	34
Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure	34
Lung Ultrasound–Guided Emergency Department Management of Acute Heart Failure (BLUSHED-AHF)	33
Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction	33
Trends in Heart Failure–Related Mortality Among Older Adults in the United States From 1999-2019	33
Chloride in Heart Failure	32
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype	32
Clinical Presentation and In-Hospital Trajectory of Heart Failure and Cardiogenic Shock	32
Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation	32
Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF	31
Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure	31
Supranormal Left Ventricular Ejection Fraction, Stroke Volume, and Cardiovascular Risk	31
Pulmonary Artery Catheter Use and Mortality in the Cardiac Intensive Care Unit	30
Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes	30
In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States	30
Outpatient Management of Heart Failure During the COVID-19 Pandemic After Adoption of a Telehealth Model	30
Hospitalization Patterns and Impact of a Magnetically-Levitated Left Ventricular Assist Device in the MOMENTUM 3 Trial	30
Predictive Value of Cardiopulmonary Exercise Testing Parameters in Ambulatory Advanced Heart Failure	29
Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure	29
Association of Social Isolation and Loneliness With Incident Heart Failure in a Population-Based Cohort Study	28
Prevalence and Prognostic Significance of Mitral Regurgitation in Acute Decompensated Heart Failure	27
Treatment of HF in an Era of Multiple Therapies	27
A Standardized and Regionalized Network of Care for Cardiogenic Shock	27
Sex-Specific Outcomes of Transcatheter Mitral-Valve Repair and Medical Therapy for Mitral Regurgitation in Heart Failure	26
Pragmatic Design of Randomized Clinical Trials for Heart Failure	26
Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure	26
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome	26
Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction	26
Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis	25
Duration of Diabetes and Incident Heart Failure	25
Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018	25
Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF	25
Impact of Temporary Percutaneous Mechanical Circulatory Support Before Transplantation in the 2018 Heart Allocation System	24
Prognostic Implications of N-Terminal Pro–B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved	24
Chemoreflex and Baroreflex Sensitivity Hold a Strong Prognostic Value in Chronic Heart Failure	24
Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium	23
Home Health Care Use and Post-Discharge Outcomes After Heart Failure Hospitalizations	23
Prognostic Value of Peak Oxygen Uptake in Patients Supported With Left Ventricular Assist Devices (PRO-VAD)	23
Pathophysiologic Processes and Novel Biomarkers Associated With Congestion in Heart Failure	23
How to Manage Heart Failure With Preserved Ejection Fraction	22
Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF	22

Prognostic Value of Global Longitudinal Strain in Patients With Heart Failure With Improved Ejection Fraction	22
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF	22
Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction	22
NT-proBNP for Risk Prediction in Heart Failure	21
Thromboembolism in Heart Failure Patients in Sinus Rhythm	21
Expenditure on Heart Failure in the United States	21
Remote Speech Analysis in the Evaluation of Hospitalized Patients With Acute Decompensated Heart Failure	21
Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction	21
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy	21
Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	21
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes	21
Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction	21
Associations Between Depressive Symptoms and HFpEF-Related Outcomes	20
The End of Endomyocardial Biopsy?	20
Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes	19
Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization	19
Association Between Thigh Muscle Fat Infiltration and Incident Heart Failure	19
Effects of a Novel Nitroxyl Donor in Acute Heart Failure	19
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction	19
Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction	19
Hemodynamically-Guided Management of Heart Failure Across the Ejection Fraction Spectrum	18
Impact of the 2018 UNOS Heart Transplant Policy Changes on Patient Outcomes	17
Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy	17
Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure	17
Empagliflozin-Induced Changes in Epicardial Fat	17
Estimating the Lifetime Benefits of Treatments for Heart Failure	16
Sequential Evaluation of NT-proBNP in Heart Failure	16
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy	16
Functional and Symptomatic Clinical Trial Endpoints	16
Tolerability of Sacubitril/Valsartan in Patients With Advanced Heart Failure	16
Spirituality in Patients With Heart Failure	15
Happy Heart Syndrome	15
Microbially Produced Imidazole Propionate Is Associated With Heart Failure and Mortality	15
Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score	15
Forgone Medical Care Associated With Increased Health Care Costs Among the U.S. Heart Failure Population	15
Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic Cardiomyopathy	15
Reclassification of Pre-Heart Failure Stages Using Cardiac Biomarkers	15
Cardiopulmonary Exercise Testing With Simultaneous Echocardiography	15
REVeAL-HF	15
Clinical Course of Patients in Cardiogenic Shock Stratified by Phenotype	15
Transvenous Right Greater Splanchnic Nerve Ablation in Heart Failure and Preserved Ejection Fraction	15
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events	15
Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan	14
Mineralocorticoid Receptor Antagonist Improves Cardiac Structure in Type 2 Diabetes	14
Early Blood Pressure Variables Associated With Improved Outcomes in VA-ECLS	14
Health Status Predicts Short- and Long-Term Risk of Composite Clinical Outcomes in Acute Heart Failure	14
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction	14
Everolimus for the Prevention of Calcineurin-Inhibitor-Induced Left Ventricular Hypertrophy After Heart Transplantation (RADTAC Study)	13
Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy	13
Soluble Neprilysin and Corin Concentrations in Relation to Clinical Outcome in Chronic Heart Failure	13
Health Care Use Before First Heart Failure Hospitalization	13
Beneficial Effects of Ketone Ester in Patients With Cardiogenic Shock	12
Cause of Death in Patients With Acute Heart Failure	12
Prognostic Value of Time in Blood Pressure Target Range Among Patients With Heart Failure	12
Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function	12
Guideline-Directed Medical Therapy Tolerability in Patients With Heart Failure and Mitral Regurgitation	12
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction	12
Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure With Reduced Ejection Fraction	12
Postimplant Phosphodiesterase-5 Inhibitor Use in Centrifugal Flow Left Ventricular Assist Devices	12
Left Ventricular Assist Devices Versus Heart Transplantation for End Stage Heart Failure is a Misleading Equivalency	12
Angiotensinogen	12
Depressive Symptoms and Incident Heart Failure Risk in the Southern Community Cohort Study	12
Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF	12
Global Variations According to Sex in Patients Hospitalized for Heart Failure in the REPORT-HF Registry	12
Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults	12
Longer-Term Effects of Remote Patient Management Following Hospital Discharge After Acute Systolic Heart Failure	11
The Addition of a Defibrillator to Resynchronization Therapy Decreases Mortality in Patients With Nonischemic Cardiomyopathy	11
Relationship of Dapagliflozin With Serum Sodium	11
Race and Socioeconomic Bias in Pediatric Cardiac Transplantation	11
Physical Activity, Subclinical Myocardial Injury, and Risk of Heart Failure Subtypes in Black Adults	11
Comparison of Demographic, Clinical, Biochemical, and Imaging Findings in Hypertrophic Cardiomyopathy Prognosis	11
Insights From HeartLogic Multisensor Monitoring During the COVID-19 Pandemic in New York City	11
Electronic Health Record-Based Deep Learning Prediction of Death or Severe Decompensation in Heart Failure Patients	11
Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic Heart Failure	10
Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States	10
Plasma Amyloid-β in Relation to Cardiac Function and Risk of Heart Failure in General Population	10
Age, Sex, and Outcomes in Heart Failure With Reduced EF	10
Increasing Utilization of Extended Criteria Donor Hearts for Transplantation	10
Promoting Diversity in Clinical Trial Leadership: A Call to Action	10
Applications of Gene Therapy in Cardiomyopathies	10

Treatment Differences in Medical Therapy for Heart Failure With Reduced Ejection Fraction Between Sociodemographic Groups	10
Cost and Value in Contemporary Heart Failure Clinical Guidance Documents	10
Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial	10
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes	10
IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction	10
Identification of Subclinical Heart Failure With Preserved Ejection Fraction in Patients With Symptomatic Atrial Fibrillation	9
Periodontal Status, C-Reactive Protein, NT-proBNP, and Incident Heart Failure	9
Contemporary Applications of Machine Learning for Device Therapy in Heart Failure	9
Management of Heart Failure–Related Cardiogenic Shock	9
1 Year HIIT and Omega-3 Fatty Acids to Improve Cardiometabolic Risk in Stage-A Heart Failure	9
Late Right Heart Failure After Left Ventricular Assist Device Implantation	9
Worsening Kidney Function Is the Major Mechanism of Heart Failure in Hypertension	9
Classifying Heart Failure in the 21st Century	9
Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF	9
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	9
Putting the “Optimal” in Optimal Medical Therapy	9
Prediction of Left Ventricular Reverse Remodeling and Outcomes by Circulating Collagen-Derived Peptides	9
Shedding Light on Latent Pulmonary Vascular Disease in Heart Failure With Preserved Ejection Fraction	9
Safety of Right and Left Ventricular Endomyocardial Biopsy in Heart Transplantation and Cardiomyopathy Patients	9
How to Initiate and Uptitrate GDMT in Heart Failure	9
Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure	8
Female Reproductive Factors and Risk of New-Onset Heart Failure	8
Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization	8
Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease	8
Life-Prolonging Benefits of LVAD Therapy in Advanced Heart Failure	8
Clinical Inertia Among Outpatients With Heart Failure	8
Prognostic Importance of Health Status Versus Functional Status in Heart Failure and Secondary Mitral Regurgitation	8
Retinal Microvasculature	8
Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan	8
Modifiable Mechanical Ventilation Targets Are Associated With Improved Survival in Ventilated VA-ECLS Patients	8
Percutaneous Mitral Valve Annuloplasty in Patients With Secondary Mitral Regurgitation and Severe Left Ventricular Enlargement	7
Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk	7
Tricuspid Regurgitation Management for Heart Failure	7
Advanced Cardiovascular Imaging in Clinical Heart Failure	7
Impact of Female Sex on Cardiogenic Shock Outcomes	7
Patient Eligibility for Established and Novel Guideline-Directed Medical Therapies After Acute Heart Failure Hospitalization	7
Patient-Reported Frailty and Functional Status in Heart Failure With Preserved Ejection Fraction	7
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure	7
Heart Rate as a Marker of Relapse During Withdrawal of Therapy in Recovered Dilated Cardiomyopathy	7
No-Implant Interatrial Shunt for HFpEF	7
Approaches to Genetic Screening in Cardiomyopathies	7
Clonal Hematopoiesis Has Prognostic Value in Dilated Cardiomyopathy Independent of Age and Clone Size	6
Challenges Facing Heart Failure Patients With Limited English Proficiency	6
Family Screening in Dilated Cardiomyopathy	6
Steroidal MRA Across the Spectrum of Renal Function	6
Hospital at Home as a Novel Care Strategy for Worsening Heart Failure	6
Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry	6
Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure	6
Risks of Depression and Suicide After Diagnosis With Heart Failure	6
Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure	6
Pulmonary Artery Pressure Monitoring Effectively Guides Management to Reduce Heart Failure Hospitalizations in Obesity	6
NT-proBNP and ICD in Nonischemic Systolic Heart Failure	6
Cardiopulmonary Exercise Testing-Based Risk Stratification in the Modern Era of Advanced Heart Failure Management	6
Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study	6
Device Interventions for Heart Failure	6
Prognostic Value of Urinary and Plasma C-Type Natriuretic Peptide in Acute Decompensated Heart Failure	6
Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction	6
Natural Language Processing for Adjudication of Heart Failure in the Electronic Health Record	6
The EAT-Lancet Diet Index, Plasma Proteins, and Risk of Heart Failure in a Population-Based Cohort	6
Impact of Diabetes on Outcomes After Transcatheter Mitral Valve Repair in Heart Failure	6
Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic V122I Transthyretin Gene Variant	6
Time Spent Engaging in Health Care Among Patients With Left Ventricular Assist Devices	6
Mineralocorticoid Receptor Antagonists and SGLT2 Inhibitor Therapy	6
Covariate Adjustment in Cardiovascular Randomized Controlled Trials	5
Prevalence of Pathogenic Variants in Cardiomyopathy-Associated Genes in Acute Myocarditis	5
Remote Dielectric Sensing Before and After Discharge in Patients With ADHF	5
Opportunities and Achievement of Medication Initiation Among Inpatients With Heart Failure With Reduced Ejection Fraction	5
Contemporary American and European Guidelines for Heart Failure Management	5
Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	5
The Effect of Using a Remote Patient Management Platform in Optimizing Guideline-Directed Medical Therapy in Heart Failure Patients	5
Socioeconomic Gradients in Mortality Following HF Hospitalization in a Country With Universal Health Care Coverage	5
Temporal Characteristics of Device-Based Individual and Integrated Risk Metrics in Patients With Chronic Heart Failure	5
Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure	5
Exercise Blood Pressure in Heart Failure With Preserved and Reduced Ejection Fraction	5
Effect of Training on Vascular Function and Repair in Heart Failure With Preserved Ejection Fraction	5
Rinse, Wash, Repeat	5
The Lure of Cardiac Metabolism in the Diagnosis, Prevention, and Treatment of Heart Failure	5
Short-Term Lactate Kinetics in Patients With Cardiogenic Shock	5
Age at Onset of Heart Failure and Subsequent Risk of Dementia	5
Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure	5
Negative Predictive Value and Prognostic Associations of Rb-82 PET/CT with Myocardial Blood Flow in CAV	5
Impact of Geographic Region on the COMMANDER-HF Trial	5
Genetic Testing for Myocarditis	5
Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status	5
Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status	5
Medication-Attributable Adverse Events in Heart Failure Trials	5
SERCA2a Agonist Effects on Cardiac Performance During Exercise in Heart Failure With Preserved Ejection Fraction	5
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF	5
Improving Health-Related Quality of Life for Women With Acute Heart Failure	5
Distinct Impact of Noncardiac Comorbidities on Exercise Capacity and Functional Status in Chronic Heart Failure	5
Complications and Mortality Following CRT-D Versus ICD Implants in Older Medicare Beneficiaries With Heart Failure	4
Fibrosis Biomarkers Predict Cardiac Reverse Remodeling	4
Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan	4
Long-Term Effects of Sotatercept on Right Ventricular Function	4
Predictors of Incident Heart Failure Diagnosis Setting	4